51
|
Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O’Meara E, Tang WW, Starling RC, Butler J, Deswal A, Felker GM, O’Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 2013; 310:2533-43. [PMID: 24247300 PMCID: PMC3934929 DOI: 10.1001/jama.2013.282190] [Citation(s) in RCA: 338] [Impact Index Per Article: 30.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
IMPORTANCE Small studies suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction; however, neither strategy has been rigorously tested. OBJECTIVE To test the 2 independent hypotheses that, compared with placebo, addition of low-dose dopamine (2 μg/kg/min) or low-dose nesiritide (0.005 μg/kg/min without bolus) to diuretic therapy will enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction. DESIGN, SETTING, AND PARTICIPANTS Multicenter, double-blind, placebo-controlled clinical trial (Renal Optimization Strategies Evaluation [ROSE]) of 360 hospitalized patients with acute heart failure and renal dysfunction (estimated glomerular filtration rate of 15-60 mL/min/1.73 m2), randomized within 24 hours of admission. Enrollment occurred from September 2010 to March 2013 across 26 sites in North America. INTERVENTIONS Participants were randomized in an open, 1:1 allocation ratio to the dopamine or nesiritide strategy. Within each strategy, participants were randomized in a double-blind, 2:1 ratio to active treatment or placebo. The dopamine (n = 122) and nesiritide (n = 119) groups were independently compared with the pooled placebo group (n = 119). MAIN OUTCOMES AND MEASURES Coprimary end points included 72-hour cumulative urine volume (decongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function end point). RESULTS Compared with placebo, low-dose dopamine had no significant effect on 72-hour cumulative urine volume (dopamine, 8524 mL; 95% CI, 7917-9131 vs placebo, 8296 mL; 95% CI, 7762-8830 ; difference, 229 mL; 95% CI, -714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, 0.01; 95% CI, -0.08 to 0.10; P = .72). Similarly, low-dose nesiritide had no significant effect on 72-hour cumulative urine volume (nesiritide, 8574 mL; 95% CI, 8014-9134 vs placebo, 8296 mL; 95% CI, 7762-8830; difference, 279 mL; 95% CI, -618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.13 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, -0.04; 95% CI, -0.13 to 0.05; P = .36). Compared with placebo, there was no effect of low-dose dopamine or nesiritide on secondary end points reflective of decongestion, renal function, or clinical outcomes. CONCLUSION AND RELEVANCE In participants with acute heart failure and renal dysfunction, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal function when added to diuretic therapy. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01132846.
Collapse
|
52
|
Fiuzat M, O’Connor CM, Gueyffier F, Mascette AM, Geller NL, Mebazaa A, Voors AA, Adams KF, Piña IL, Neyses L, Muntendam P, Felker GM, Pitt B, Zannad F, Bristow MR. Biomarker-Guided Therapies in Heart Failure: A Forum for Unified Strategies. J Card Fail 2013; 19:592-9. [DOI: 10.1016/j.cardfail.2013.05.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2013] [Revised: 05/16/2013] [Accepted: 05/20/2013] [Indexed: 12/17/2022]
|
53
|
Ahmad T, O’Connor CM. Therapeutic Implications of Biomarkers in Chronic Heart Failure. Clin Pharmacol Ther 2013; 94:468-79. [DOI: 10.1038/clpt.2013.139] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2013] [Accepted: 07/08/2013] [Indexed: 11/09/2022]
|
54
|
|
55
|
Ambrosy AP, Fonarow GC, Albert NM, Curtis AB, Heywood JT, Mehra MR, O’Connor CM, Reynolds D, Walsh MN, Yancy CW, Gheorghiade M. B-type natriuretic peptide assessment in ambulatory heart failure patients. J Cardiovasc Med (Hagerstown) 2012; 13:360-7. [DOI: 10.2459/jcm.0b013e328353128c] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
56
|
Mentz RJ, Fiuzat M, Kraft M, Lindenfeld J, O’Connor CM. Bronchodilators in Heart Failure Patients With COPD: Is It Time for a Clinical Trial? J Card Fail 2012; 18:413-22. [DOI: 10.1016/j.cardfail.2012.02.002] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2011] [Revised: 01/30/2012] [Accepted: 02/01/2012] [Indexed: 12/22/2022]
|
57
|
Teerlink JR, Iragui VJ, Mohr JP, Carson PE, Hauptman PJ, Lovett DH, Miller AB, Piña IL, Thomson S, Varosy PD, Zile MR, Cleland JG, Givertz MM, Metra M, Ponikowski P, Voors AA, Davison BA, Cotter G, Wolko D, DeLucca P, Salerno CM, Mansoor GA, Dittrich H, O’Connor CM, Massie BM. The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment. Drug Saf 2012; 35:233-44. [DOI: 10.2165/11594680-000000000-00000] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
58
|
Joynt KE, O’Connor CM. Prognostic Implications of Depression in Ischemic Syndromes. Coron Artery Dis 2012. [DOI: 10.1007/978-1-84628-712-1_13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
59
|
O’Connor CM, Fiuzat M. Lessons Learned from Clinical Trials in Acute Heart Failure: Phase 3 Drug Trials. Heart Fail Clin 2011; 7:451-6. [DOI: 10.1016/j.hfc.2011.06.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
60
|
Walsh MN, Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, O’Connor CM, Inge PJ, Mehra MR, Reynolds D, Yancy CW. EQUITABLE IMPROVEMENT FOR WOMEN AND MEN IN THE USE OF GUIDELINE-RECOMMENDED THERAPIES FOR HEART FAILURE: FINDINGS FROM IMPROVE HF. J Am Coll Cardiol 2010. [DOI: 10.1016/s0735-1097(10)61331-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
61
|
Piccini JP, Hellkamp AS, Whellan DJ, Ellis SJ, Keteyian SJ, Cooper L, Kraus WE, Piña IL, O’Connor CM. EXERCISE TRAINING AND IMPLANTABLE CARDIOVERTER DEFIBRILLATOR SHOCKS IN PATIENTS WITH HEART FAILURE: RESULTS FROM HF-ACTION. J Am Coll Cardiol 2010. [DOI: 10.1016/s0735-1097(10)60094-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
62
|
O’Connor CM, Wojdyla D, Leifer E, Ellis S, Lee K, Clare R, Pina I, Keteyian S, Kitzman D, Kraus W, Rendall D, Cooper L, Whellan D. DETERMINANTS OF MORBIDITY AND MORTALITY IN CHRONIC HEART FAILURE (CHF) WITH SYSTOLIC DYSFUNCTION: RESULTS OF THE HF-ACTION PREDICTIVE MODEL. J Am Coll Cardiol 2010. [DOI: 10.1016/s0735-1097(10)60271-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
63
|
O’Connor CM, Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Inge PJ, Mehra MR, Reynolds D, Walsh MN, Yancy CW. RELATIONSHIP BETWEEN CARDIOLOGY PRACTICE TEACHING STATUS AND IMPROVEMENT IN THE USE OF EVIDENCE-BASED THERAPY FOR HEART FAILURE: FINDINGS FROM IMPROVE HF. J Am Coll Cardiol 2010. [DOI: 10.1016/s0735-1097(10)61213-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
64
|
Weatherley BD, Milo-Cotter O, Michael Felker G, Uriel N, Kaluski E, Vered Z, O’Connor CM, Adams KF, Cotter G. Early worsening heart failure in patients admitted with acute heart failure - a new outcome measure associated with long-term prognosis? Fundam Clin Pharmacol 2009; 23:633-9. [DOI: 10.1111/j.1472-8206.2009.00697.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
65
|
Milo-Cotter O, Cotter G, Kaluski E, Rund MM, Felker GM, Adams KF, O’Connor CM, Weatherley BD. Rapid Clinical Assessment of Patients with Acute Heart Failure: First Blood Pressure and Oxygen Saturation – Is That All We Need? Cardiology 2009; 114:75-82. [DOI: 10.1159/000213051] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/24/2008] [Accepted: 12/11/2008] [Indexed: 11/19/2022]
|
66
|
O’Connor CM, Cree GS, McRae K. Conceptual Hierarchies in a Flat Attractor Network: Dynamics of Learning and Computations. Cogn Sci 2009; 33:665-708. [PMID: 19543434 PMCID: PMC2699208 DOI: 10.1111/j.1551-6709.2009.01024.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The structure of people's conceptual knowledge of concrete nouns has traditionally been viewed as hierarchical (Collins & Quillian, 1969). For example, superordinate concepts (vegetable) are assumed to reside at a higher level than basic-level concepts (carrot). A feature-based attractor network with a single layer of semantic features developed representations of both basic-level and superordinate concepts. No hierarchical structure was built into the network. In Experiment and Simulation 1, the graded structure of categories (typicality ratings) is accounted for by the flat attractor-network. Experiment and Simulation 2 show that, as with basic-level concepts, such a network predicts feature verification latencies for superordinate concepts (vegetable ). In Experiment and Simulation 3, counterintuitive results regarding the temporal dynamics of similarity in semantic priming are explained by the model. By treating both types of concepts the same in terms of representation, learning, and computations, the model provides new insights into semantic memory.
Collapse
|
67
|
Allen LA, Rogers JG, Warnica JW, DiSalvo TG, Tasissa G, Binanay C, O’Connor CM, Califf RM, Leier CV, Shah MR, Stevenson LW. High mortality without ESCAPE: the registry of heart failure patients receiving pulmonary artery catheters without randomization. J Card Fail 2008; 14:661-9. [PMID: 18926438 PMCID: PMC2592194 DOI: 10.1016/j.cardfail.2008.05.004] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2008] [Revised: 04/29/2008] [Accepted: 05/08/2008] [Indexed: 01/26/2023]
Abstract
BACKGROUND In the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE), there was no difference in days alive and out of the hospital for patients with decompensated heart failure randomly assigned to therapy guided by pulmonary artery catheter (PAC) plus clinical assessment versus clinical assessment alone. The external validity of these findings is debated. METHODS AND RESULTS ESCAPE sites enrolled 439 patients receiving PAC without randomization in a prospective registry. Baseline characteristics, pertinent trial exclusion criteria, reasons for PAC use, hemodynamics, and complications were collected. Survival was determined from the National Death Index and the Alberta Registry. On average, registry patients had lower blood pressure, worse renal function, less neurohormonal antagonist therapy, and higher use of intravenous inotropes compared with trial patients. Although clinical assessment anticipated less volume overload and greater hypoperfusion among the registry population, measured filling pressures were similarly elevated in the registry and trial patients, whereas measured perfusion was slightly higher among registry patients. Registry patients had longer hospitalization (13 vs 6 days, P < .001) and higher 6-month mortality (34% vs 20%, P < .001) than trial patients. CONCLUSIONS The decision to use PAC without randomization identified a population with higher disease severity and risk of mortality. This prospective registry highlights the complex context of patient selection for randomized trials.
Collapse
|
68
|
Klein L, Massie BM, Leimberger JD, O’Connor CM, Piña IL, Adams KF, Califf RM, Gheorghiade M. Admission or Changes in Renal Function During Hospitalization for Worsening Heart Failure Predict Postdischarge Survival. Circ Heart Fail 2008; 1:25-33. [DOI: 10.1161/circheartfailure.107.746933] [Citation(s) in RCA: 208] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Background—
Admission measures of renal function (blood urea nitrogen [BUN], estimated glomerular filtration rate [eGFR]) in patients hospitalized for worsening heart failure are predictors of in-hospital outcomes. Less is known about the changes and relationships among these variables and the postdischarge survival rate.
Methods and Results—
In a retrospective analysis of 949 patients from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure, we investigated the relation between admission values and changes in BUN and eGFR and rate of death by 60 days after discharge. On admission, median eGFR was 51 mL � min
−1
� 1.73 m
−2
(interquartile range, 37 to 70 mL � min
−1
� 1.73 m
−2
), and BUN was 25 mg/dL (interquartile range, 17 to 41 mg/dL). On average, there was a 1.1–mL � min
−1
� 1.73 m
−2
decrease in eGFR and a 4.7-mg/dL increase in BUN from admission to discharge. By discharge, 12% of patients had a >25% decrease in eGFR, and 39% had a >25% increase in BUN. Although both lower admission eGFR and higher admission BUN were associated with higher risk of death by 60 days after discharge, multivariable-adjusted Cox proportional-hazards analysis showed that BUN was a stronger predictor of death by 60 days than was eGFR (χ
2
, 11.6 and 0.6 for BUN and eGFR, respectively). Independently of admission values, an increase of ≥10 mg/dL in BUN during hospitalization was associated with worse 60-day survival rate: BUN (per 5-mg/dL increase) had a hazard ratio of 1.08 (95% CI, 1.01 to 1.16). Although milrinone treatment led to a minor improvement in renal function by discharge, the 60-day death and readmission rates were similar between the milrinone and placebo groups.
Conclusions—
A substantial number of patients admitted with heart failure have worsening renal function during hospitalization. Higher admission BUN and increasing BUN during hospitalization, independently of admission values, are associated with a worse survival rate. Use of milrinone in these high-risk patients does not improve outcomes despite minor improvements in the renal function.
Collapse
|
69
|
Shah MR, Hasselblad V, Tasissa G, Christenson RH, Binanay C, O’Connor CM, Ohman EM, Stevenson LW, Califf RM. Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). Am J Cardiol 2007; 100:1427-33. [PMID: 17950802 DOI: 10.1016/j.amjcard.2007.06.035] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2007] [Revised: 06/10/2007] [Accepted: 06/10/2007] [Indexed: 10/22/2022]
Abstract
Rapid-assay biomarkers may predict outcomes in patients with decompensated heart failure (HF). This study assessed whether rapid-assay B-type natriuretic peptide (BNP) and troponin I predicts length of stay and mortality and correlates with pulmonary artery catheter (PAC)-derived hemodynamics in patients hospitalized with acute HF. There were 141 nonconsecutive patients in this prospective cohort study of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE), a randomized trial testing PACs in 433 patients with severe decompensated HF. Biomarkers were drawn at baseline and discharge and when the first, second, and final hemodynamics were obtained in 69 patients randomly assigned to PACs. Cox analysis was used to model mortality, length of stay, and rehospitalization, and Pearson's correlations were used to describe the relation among BNP, troponin I, and PAC-derived hemodynamics. The median (25th percentile, 75th percentile) BNP levels were 783 pg/ml (329, 1,565) at baseline and 468 pg/ml (240, 946) at discharge. After treatment for HF, the median BNP level decreased by 144 pg/ml (-653, 55; p = 0.004). Patients with baseline BNP levels >1,500 pg/ml had greater mortality at 6 months and almost twice the length of stay as patients with BNP levels <500 pg/ml (10.1 vs 5.7 days, p = 0.002). Troponin I did not predict these outcomes. First BNP correlated modestly with first right atrial pressure (r = 0.47, p = 0.005) and first pulmonary capillary wedge pressure (r = 0.54, p = 0.001). Final BNP correlated modestly with final right atrial pressure (r = 0.63, p = 0.001). In conclusion, patients with BNP >1,500 pg/ml had greater mortality and longer length of stay than patients with BNP <500 pg/ml. BNP decreased after hospitalization, but correlated modestly with PAC-derived hemodynamics. Rapid-assay BNP may provide information that helps physicians decide when to pursue more aggressive and invasive therapies.
Collapse
|
70
|
Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, Kaplan NM, O’Connor CM, O’Gara PT, Oparil S. REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. Hypertension 2007. [DOI: 10.1161/hypertensionaha.107.183885] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
71
|
Harrington RA, O’Connor CM, Stein JH, Wolff MR, McLean RC, Mohler ER, Blumenthal RS, Knopf WD, Ambrose JA, Wagoner LE, Starling RC, Kim RJ, Markowitz SM, Landzberg MJ, Ungerleider R, Rahimtoola SH, Resnic FS, Foody J. Highlights of the 55th Annual Scientific Session of the American College of Cardiology—March 11–14, 2006. J Am Coll Cardiol 2006. [DOI: 10.1016/j.jacc.2006.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
72
|
Harrington RA, O’Connor CM, Stein JH, Wolff MR. An Introduction. J Am Coll Cardiol 2006. [DOI: 10.1016/j.jacc.2006.04.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
73
|
Felker GM, Gattis WA, Adams KF, O’Connor CM. Reply. J Am Coll Cardiol 2005. [DOI: 10.1016/j.jacc.2005.02.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
74
|
Bourque JM, Velazquez EJ, Borges-Neto S, Hasselblad V, O’Connor CM. A Reappraisal of Myocardial Viability Testing in Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Can Meta-Analysis Be Trusted? ACTA ACUST UNITED AC 2002. [DOI: 10.1159/000065943] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
75
|
Hathaway WR, McNulty SE, Pieper K, Harrell FE, Mark DB, Jones RH, Bashore TM, Califf RM, O’Connor CM. 901-84 Prognostic Value of Right Heart Catheterization Hemodynamic Data in Surgically Treated Patients with Coronary Artery Disease. J Am Coll Cardiol 1995. [DOI: 10.1016/0735-1097(95)91561-b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|